Document is current
Any future updates will be listed below
-
Authors
Tatetsu, Hiro https://orcid.org/0000-0001-8131-3401
Higuchi, Yusuke
Shichijo, Takafumi
Oda, Kazutaka
Nakata, Hirotomo
Yasunaga, Jun-ichirou
Nosaka, Kisato
Matsuoka, Masao
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K08420)
- License Information
-
More Information
Article History
Received: 3 May 2023
Revised: 14 June 2023
Accepted: 19 June 2023
First Online: 28 June 2023
Declarations
:
: HT has received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Novartis, SymBio Pharmaceuticals Limited, and Takeda Pharmaceutical, Meiji Seika Pharma as well as patents and royalties from Mesoblasts. KN has received consultancy fees, research funding, honoraria from Kyowa Kirin, research funding from Chugai Pharmaceutical, and honoraria from Celgene, Eisai, Meiji Seika Pharma, Janssen Pharmaceutical, Abbvie Inc., and Bristol Myers Squibb. MM received research funding from Chugai Pharmaceuticals and Kyowa Kirin. YH, TS, KO, HN, J-iY have no conflicts of interest to declare.
: This study was approved by the Institutional Review Board of Kumamoto University Hospital (No. 2226) and was conducted in accordance with the principles of the Declaration of Helsinki.
